BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28489605)

  • 21. Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays.
    Caprini E; Cristofoletti C; Arcelli D; Fadda P; Citterich MH; Sampogna F; Magrelli A; Censi F; Torreri P; Frontani M; Scala E; Picchio MC; Temperani P; Monopoli A; Lombardo GA; Taruscio D; Narducci MG; Russo G
    Cancer Res; 2009 Nov; 69(21):8438-46. PubMed ID: 19843862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome.
    Woollard WJ; Pullabhatla V; Lorenc A; Patel VM; Butler RM; Bayega A; Begum N; Bakr F; Dedhia K; Fisher J; Aguilar-Duran S; Flanagan C; Ghasemi AA; Hoffmann RM; Castillo-Mosquera N; Nuttall EA; Paul A; Roberts CA; Solomonidis EG; Tarrant R; Yoxall A; Beyers CZ; Ferreira S; Tosi I; Simpson MA; de Rinaldis E; Mitchell TJ; Whittaker SJ
    Blood; 2016 Jun; 127(26):3387-97. PubMed ID: 27121473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
    van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
    J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Mutations Involving NF-κB and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome.
    Kim EJ; Lewis DJ; Duvic M
    J Invest Dermatol; 2017 Sep; 137(9):1831-1833. PubMed ID: 28843295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations.
    Mitani Y; Liu B; Rao PH; Borra VJ; Zafereo M; Weber RS; Kies M; Lozano G; Futreal PA; Caulin C; El-Naggar AK
    Clin Cancer Res; 2016 Feb; 22(3):725-33. PubMed ID: 26631609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EPHA4 is overexpressed but not functionally active in Sézary syndrome.
    Hameetman L; van der Fits L; Zoutman WH; Out-Luiting JJ; Siegal G; de Esch IJ; Vermeer MH; Tensen CP
    Oncotarget; 2015 Oct; 6(31):31868-76. PubMed ID: 26376612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.
    Ungewickell A; Bhaduri A; Rios E; Reuter J; Lee CS; Mah A; Zehnder A; Ohgami R; Kulkarni S; Armstrong R; Weng WK; Gratzinger D; Tavallaee M; Rook A; Snyder M; Kim Y; Khavari PA
    Nat Genet; 2015 Sep; 47(9):1056-60. PubMed ID: 26258847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation.
    Jones CL; Wain EM; Chu CC; Tosi I; Foster R; McKenzie RC; Whittaker SJ; Mitchell TJ
    J Invest Dermatol; 2010 Apr; 130(4):1116-25. PubMed ID: 19759548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3.
    Booken N; Gratchev A; Utikal J; Weiss C; Yu X; Qadoumi M; Schmuth M; Sepp N; Nashan D; Rass K; Tüting T; Assaf C; Dippel E; Stadler R; Klemke CD; Goerdt S
    Leukemia; 2008 Feb; 22(2):393-9. PubMed ID: 18033314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clonal nature of circulating Sezary cells.
    Weinberg JM; Jaworsky C; Benoit BM; Telegan B; Rook AH; Lessin SR
    Blood; 1995 Dec; 86(11):4257-62. PubMed ID: 7492785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing.
    Andersson E; Eldfors S; Edgren H; Ellonen P; Väkevä L; Ranki A; Mustjoki S
    Exp Dermatol; 2014 May; 23(5):366-8. PubMed ID: 24689486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome.
    Braun FC; Grabarczyk P; Möbs M; Braun FK; Eberle J; Beyer M; Sterry W; Busse F; Schröder J; Delin M; Przybylski GK; Schmidt CA
    Leukemia; 2011 Sep; 25(9):1494-501. PubMed ID: 21625233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Analysis of cloning rearrangement of T-cell receptor gamma gene in primary cutaneous lymphoma].
    Pawlaczyk M; Kistowska M; Poreba E; Filas V; Breborowicz J; Goździcka-Józefiak A
    Pol Merkur Lekarski; 2003 Nov; 15(89):420-3. PubMed ID: 14969134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TOX expression in different subtypes of cutaneous lymphoma.
    Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic alterations in Sezary syndrome.
    Iżykowska K; Przybylski GK
    Leuk Lymphoma; 2011 May; 52(5):745-53. PubMed ID: 21323514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mycosis fungoides and Sézary syndrome.
    Espinet B; Salgado R
    Methods Mol Biol; 2013; 973():175-88. PubMed ID: 23412790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenomic Analysis of Sézary Syndrome Defines Patterns of Aberrant DNA Methylation and Identifies Diagnostic Markers.
    van Doorn R; Slieker RC; Boonk SE; Zoutman WH; Goeman JJ; Bagot M; Michel L; Tensen CP; Willemze R; Heijmans BT; Vermeer MH
    J Invest Dermatol; 2016 Sep; 136(9):1876-1884. PubMed ID: 27113428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome.
    Brito-Babapulle V; Hamoudi R; Matutes E; Watson S; Kaczmarek P; Maljaie H; Catovsky D
    Br J Haematol; 2000 Jul; 110(1):180-7. PubMed ID: 10930996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sézary syndrome without erythroderma.
    Henn A; Michel L; Fite C; Deschamps L; Ortonne N; Ingen-Housz-Oro S; Marinho E; Beylot-Barry M; Bagot M; Laroche L; Crickx B; Maubec E
    J Am Acad Dermatol; 2015 Jun; 72(6):1003-9.e1. PubMed ID: 25981000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.